Astral Codex Ten

EU

4 min read

EU

Article

EU is a recurring place in the Astral Codex Ten archive, appearing 5 times across 5 issues between January 27, 2022 and January 06, 2026. The archive places it in contexts such as “One of the other major differences between the US healthcare system and the EU systems”; “drug approvals for all of the EU”; “In the United States (and EU) banks and payment processors”. It most often appears alongside United States, US, FDA.

Metadata

  • Category: Places
  • Mention count: 5
  • Issue count: 5
  • First seen: January 27, 2022
  • Last seen: January 06, 2026

Appears In

Source Context

Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.

Highlights From The Comments On Health Care Systems
January 27, 2022 · Original source
One of the other major differences between the US healthcare system and the EU systems is that the European Commission does drug approvals for all of the EU (and there are other EU-wide paths to getting drugs approved, with approval by any regulatory body being sufficient for the drug to be approved); whereas, the FDA does approvals for just the US (and it doesn't compete with any other US regulators to do the approvals). This gives individual European countries much more leverage than the US would have for negotiating with drug manufacturers. Since most of the cost of drug manufacturing is the research, trials, and approval process, Norway (technically a non-EU member of the EEA, but they still accept approvals given by the European Commission) can offer drugmakers relatively low prices and still have them sell their drugs there because they're already going through the European Commission approval process to sell their drugs in the rest of Europe. If the USA starts setting drug prices particularly low, it will have a much bigger impact on the incentive to fund drug trials through the FDA approval process. This also changes the optics dramatically. There's not going to be a scandal over a drugmaker failing to push their drugs through the approval process the same way there would be over it refusing to sell drugs to a particular country where those drugs are approved. (And I think it's generally accepted that the FDA's process is slower, more stringent, and more expensive than Europe's.)
Links For April
April 14, 2022 · Original source
30: Pro-crypto manifesto: “There are no constitutional rights in substance without freedom to transact […] Freedom of speech might require pamplets, advertisements, or websites. Freedom of assembly might require taking a train to Washington DC or booking a hotel room…the exercise of rights costs money…In the United States (and EU) banks and payment processors have been pressured to cut off accounts to gun shops, adult businesses, crypto businesses and other perfectly legal businesses….Some aspiring dictator will censor their opponents' spending during a election period and they won't be able to buy a tomato, let alone run a campaign.”
Inline links: Pro-crypto manifesto
Semaglutidonomics
November 24, 2022 · Original source
No direct inline source block was recovered for this mention.
ACX Grants 1-3 Year Updates
June 18, 2025 · Original source
No direct inline source block was recovered for this mention.
Highlights From The Comments On Boomers
January 06, 2026 · Original source
No direct inline source block was recovered for this mention.